Laura Marbun
Family · Topeka, KSNPI 1548718935
Payments from drug & device makers
Across 141 payments — averaging $24.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$1K
- Neurocrine Biosciences, Inc.$681
- E.r. Squibb & Sons, L.L.C.$363
- Alkermes, Inc.$220
- Otsuka America Pharmaceutical, Inc.$214
- Acadia Pharmaceuticals Inc$173
- plus $774 from 15 others
What the payments were for
- Food & beverage$3,27694%
- Education$2166%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 42 | $1,068 |
| Neurocrine Biosciences, Inc. | 19 | $681 |
| E.r. Squibb & Sons, L.L.C. | 13 | $363 |
| Alkermes, Inc. | 11 | $220 |
| Otsuka America Pharmaceutical, Inc. | 13 | $214 |
| Acadia Pharmaceuticals Inc | 5 | $173 |
| Johnson & Johnson | 6 | $120 |
| Axsome Therapeutics, Inc. | 6 | $119 |
| Almatica Pharma LLC | 6 | $117 |
| Next Science LLC | 3 | $87 |
| Noven Therapeutics, LLC | 4 | $69 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $56 |
| AbbVie | 2 | $45 |
| Hydrofera LLC | 1 | $25 |
| KCI USA, Inc. | 1 | $23 |
| Janssen Scientific Affairs, LLC | 1 | $22 |
| Eisai Inc. | 1 | $21 |
| Kerecis Limited | 1 | $20 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Lundbeck LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Austedo XR$242
- INGREZZA$122
- NUPLAZID$109
How this compares
$3,492 in reported general payments places this provider in the 90th percentile of 1,579 family providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BriviactBrivaracetam | 26 | $18,344 |
| Clonazepam | 164 | $2,613 |
| Lorazepam | 95 | $1,529 |
| Tramadol Hcl | 23 | $372 |
| Risperidone | 13 | $150 |
| Alprazolam | 17 | $121 |
Paid to pharmacies, not to this prescriber.
Other family in Topeka
- Tatum TolandTopeka$108K
- Ansley McKennaTopeka$8K
- Jason CrenshawTopeka$7K
- Zohra HussainiKansas City$329K
- Jennifer ChesterOverland Park$327K
- Amanda CaldwellLeawood$203K
- Kayla del RioWichita$147K
- Kelli RiceWichita$114K
- Mary GonzalesWichita$87K
- Erin FeitzOverland Park$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.